Rondeau, Stephanie

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 4.

Journal Article

Zucca, Emanuele; Rondeau, Stephanie; Vanazzi, Anna; Østenstad, Bjørn; Mey, Ulrich J. M.; Rauch, Daniel; Wahlin, Björn E.; Hitz, Felicitas; Hernberg, Micaela; Johansson, Ann-Sofie; de Nully Brown, Peter; Hagberg, Hans; Ferreri, Andrés J. M.; Lohri, Andreas; Novak, Urban; Zander, Thilo; Bersvendsen, Hanne; Bargetzi, Mario; Mingrone, Walter; Krasniqi, Fatime; ... (2019). Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 134(4), pp. 353-362. American Society of Hematology 10.1182/blood-2018-10-879643

Driessen, Christoph; Müller, Rouven; Novak, Urban; Cantoni, Nathan; Betticher, Daniel; Mach, Nicolas; Rüfer, Axel; Mey, Ulrich; Samaras, Panagiotis; Ribi, Karin; Besse, Lenka; Besse, Andrej; Berset, Catherine; Rondeau, Stephanie; Hawle, Hanne; Hitz, Felicitas; Pabst Müller, Thomas Niklaus; Zander, Thilo (2018). Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood, 132(19), pp. 2097-2100. American Society of Hematology 10.1182/blood-2018-05-851170

Voegeli, Michèle; Rondeau, Stephanie; Berardi Vilei, Simona; Lerch, Erika; Wannesson, Luciano; Pabst, Thomas; Rentschler, Jochen; Bargetzi, Mario; Jost, Lorenz; Ketterer, Nicolas; Bischof Delaloye, Angelika; Ghielmini, Michele (2017). Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematological oncology, 35(4), pp. 576-583. Wiley 10.1002/hon.2348

Hitz, Felicitas; Zucca, Emanuele; Pabst, Thomas; Fischer, Natalie; Cairoli, Anne; Samaras, Panagiotis; Caspar, Clemens B; Mach, Nicolas; Krasniqi, Fatime; Schmidt, Adrian; Rothermundt, Christian; Enoiu, Milica; Eckhardt, Katrin; Berardi Vilei, Simona; Rondeau, Stephanie; Mey, Ulrich (2016). Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. British journal of haematology, 174(2), pp. 255-263. Wiley-Blackwell 10.1111/bjh.14049

This list was generated on Fri Mar 29 06:19:32 2024 CET.
Provide Feedback